Adverse Effects Profile of Dicycloplatin (DCP) Offers Chemotherapeutic Advantage over Cisplatin and Carboplatin

Details

• Personal Author:
  Cecil C ; Crigger C ; Guo Y ; Hogan T ; Jiang B-H ; Jiao S ; Liang X ; Morley C ; Salkini MW ; Washington IM ; Williams DJ ; Winn AC ; Yan B ; Yang X ; Yu JJ ; Zheng J
• Description:
  Background/Aim: Platinum-based chemotherapy often fails due to its severe adverse effects. The aim of this study was to examinethe adverse effects profile and efficacy of dicycloplatin and compare them to those of cisplatin and carboplatin. Materialsand Methods: Cystoscopy surveillance of the first American cancer patient treated with dicycloplatin was performed quarterly.In vitro and in vivo studies were conducted using immunoblotting and flow cytometry to assess immune status of spleen andbone marrow of mice treated with dicycloplatin, cisplatin and carboplatin. Results: The American patient did not suffer clinicallysignificant myelosuppression; dicycloplatin has sustained remission in this patient to date. Experimental studies showed thatdicycloplatin is less toxic to bone marrow and spleen of mice than cisplatin and carboplatin. Conclusion: Dicycloplatin isa promising drug in cancer chemotherapy with less aggressive side-effects than those typically associated with cisplatin andcarboplatin. This is an important therapeutic advantage in cancer chemotherapy. Clinical investigation of dicycloplatin asan alternative to cisplatin or carboplatin is warranted. [Description provided by NIOSH]
• Subjects:
  Animals Laboratories Neoplasms Occupational Health Safety
• Keywords:
  Author Keywords: Chemotherapy Cancer Chemotherapy Cytometric Analysis DCP Dicycloplatin Health Effects In Vitro Studies In Vivo Studies Laboratory Animals Platinum Surveillance Therapeutic Advance Tolerable Side Effects

  More +
• ISSN:
  0250-7005
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  Iowa ; OSHA Region 3 ; OSHA Region 7 ; West Virginia
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  HELD - Health Effects Laboratory Division
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  39
• Issue:
  8
• NIOSHTIC Number:
  nn:20056978
• Citation:
  Anticancer Res 2019 Aug; 39(8):4455-4462
• Contact Point Address:
  Jing Jie Yu, MD, WVU Cancer Institute, P.O. Box 9300, Morgantown, WV 26506
• Email:
  jyu@hsc.wvu.edu
• CAS Registry Number:
  Platinum (CAS RN 7440-06-4)
• Federal Fiscal Year:
  2019
• Peer Reviewed:
  True
• Source Full Name:
  Anticancer Research: international journal of cancer research and treatment
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:989f9ec9460d9ab93416caed1a2e8916d32de21b3157c8c3d1f56365c1c64fbea238cec2b3af39e640b060df42fd4b502b028f27c4b0ed8386b14eba92a7c9e5
• Download URL:
  https://stacks.cdc.gov/view/cdc/214465/cdc_214465_DS1.pdf
• File Type:
  [PDF - 399.58 KB ]